Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
25 March 2024 - 11:00PM
UK Regulatory
Smith+Nephew teams up with UFC to be first-ever Preferred Sports
Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces it has been named the Preferred Sports
Medicine Technology Partner of UFC – the world’s premier mixed
martial arts organization and one of the foremost global brands in
all of sports. Under the terms of the multi-year partnership,
Smith+Nephew will activate its brand through UFC’s immense global
presence to promote the repair, regeneration and recovery of Sports
Medicine injuries through advanced technologies.
“We’re thrilled to have Smith+Nephew join us for the first time
as an Official UFC Partner,” said Robby Miller, Vice President, UFC
Global Partnerships. “Through hard work, significant investment,
and groundbreaking innovations like the UFC Performance Institute,
UFC has become the industry leader in athlete health and safety in
combat sports. We’re looking forward to advancing that mission by
also promoting better health and recovery through technology
solutions, such as those offered by Smith+Nephew, that will benefit
UFC athletes and fans alike.”
Smith+Nephew offers world-class Sports Medicine solutions
including advanced technologies, instruments and implants that
enable surgeons to perform minimally invasive surgery including the
repair of soft tissue injuries and degenerative conditions of the
shoulder, knee, hip and small joints. Recent advancements in its
biological healing portfolio include the REGENETEN◊
Bioinductive Implant and the newly acquired CARTIHEAL◊
AGILI-C◊ Cartilage Repair Implant. Backed by impressive
clinical evidence, both technologies are transforming the way
healthcare professionals treat soft tissue repair and helping
improve patient outcomes versus the current standard of
care.1,2
“Smith+Nephew’s purpose is Life Unlimited – helping restore
people’s bodies and their self-belief by using technology to take
the limits off living. We are proud to partner with UFC and share a
common goal to get patients back in the game quickly, safely, and
effectively,” said Scott Schaffner, President Sports Medicine,
Smith+Nephew. “The global reach and influence of UFC is unmatched
by any other sports organization, and we look forward to this
partnership spotlighting Smith+Nephew’s leading-edge portfolio of
Sports Medicine technology solutions with the UFC’s global
audience.”
Beyond the Octagon, UFC and Smith+Nephew will collaborate on
original content that will be distributed through UFC’s popular
digital and social channels, which reach more than 259 million
users worldwide. Smith+Nephew will also have a branded presence
throughout the UFC Performance Institutes in Las Vegas, Shanghai
and Mexico City - the world’s first mixed martial arts performance
training, research, rehabilitation, and nutrition centers. The
agreement also provides for an annual Brand Ambassador fund that
will bring the partnership to life through appearances, content,
and creative campaigns with UFC athletes.
- ends -
Enquiries
Media
David Snyder
+1 978-749-1440
Smith+Nephew
|
|
|
|
|
|
References
- Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based
Scaffold Versus Microfracture and Debridement for the Treatment of
Knee Chondral and Osteochondral Lesions: Results of a Multicenter
Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967.
doi:10.1177/03635465231151252
- Ruiz Ibán MA, Navlet MG, Marco SM, et al. Augmentation of
a transosseous equivalent repair in posterosuperior non-acute
rotator cuff tears with a bioinductive collagen implant decreases
the re-tear rate at one year. A randomised controlled trial.
Arthroscopy. Published online 12/27/2023.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on
the repair, regeneration and replacement of soft and hard tissue.
We exist to restore people’s bodies and their self-belief by using
technology to take the limits off living. We call this purpose
‘Life Unlimited’. Our 18,000 employees deliver this mission every
day, making a difference to patients’ lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global business units of
Orthopaedics, Sports Medicine & ENT and Advanced Wound
Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
About UFC®
UFC® is the world’s premier mixed martial arts organization (MMA),
with more than 700 million fans and 259 million social media
followers. The organization produces more than 40 live events
annually in some of the most prestigious arenas around the world
while broadcasting to over 975 million TV households across more
than 170 countries. UFC’s athlete roster features the world’s best
MMA athletes representing more than 80 countries. The
organization’s digital offerings include UFC FIGHT PASS®, one of
the world’s leading streaming services for combat sports. UFC is
part of TKO Group Holdings (NYSE: TKO) and is headquartered in Las
Vegas, Nevada. For more information, visit UFC.com and follow UFC
at Facebook.com/UFC and @UFC on X, Snapchat, Instagram, and TikTok:
@UFC.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain
marks registered in US Patent and Trademark Office.
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Mar 2024 to Apr 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2023 to Apr 2024